Indivior sales drop 9% on higher rebates; India's Alkem Labs plots $210M IPO;

@FiercePharma: ICYMI yesterday: FDA cites Pfizer for shortfalls at Chinese manufacturing plant. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Express Scripts looks into pharmacies at AbbVie, Teva in wake of Valeant's Philidor saga. Article | Follow @CarlyHFierce

> The Reckitt Benckiser pharma spinoff Indivior saw sales decline 9% for the first nine months of 2015, to $766 million from $844 million last year; the company cited lower market share and higher rebates as causes. Release

> The Indian drugmaker Alkem Laboratories is planning an initial public offering worth about $210 million, hoping to launch it next month. Report

> Merck KGaA's extended-release form of Glucophage won a new approval for diabetes patients with moderate kidney insufficiency and chronic heart failure. Release

Medical Device News

@FierceMedDev: ICYMI: Drug-device combo from Wyss takes a new approach on treating stroke. FierceBiotechResearch story | Follow @FierceMedDev

@EmilyWFierce: Flowonix teams with Connecticut provider for implant of drug delivery infusion pump. Article | Follow @EmilyWFierce

> Neuromodulator and artificial kidney to be reviewed under FDA's Expedited Access Pathway. More

> Fractyl gains traction with balloon ablation device for Type 2 diabetes. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Merck KGaA inks cancer metabolism drug discovery alliance with Selvita. Article | Follow @FierceBiotech

@JohnCFierce: Gates, Hopp back $110M megaround for CureVac's mRNA work. News | Follow @JohnCFierce

@DamianFierce: Wait can we reconvene Grantland just to deal with this image? More | Follow @DamianFierce

> Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners. Story

> GSK forms Keytruda combo trial pact as it plots path to 20 filings by 2020. Article

Drug Delivery News

> Amgen's Imlygic becomes first re-engineered virus to earn FDA approval as a cancer fighter. Item

> Pfizer's sickle cell anemia candidate enters trials, to the delight of delivery partner Halozyme. Story

> Imaging nanoparticle puts the heat to ovarian cancer cells. Article

> Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Report

> Novartis' inhaler for COPD gets FDA approval. More

Pharma Manufacturing News

> Bain-backed compounding upstart adds second Texas manufacturing facility. Item

> Struggling Daiichi again stumbles with vaccine production. More

> First prefab biologics plant goes up in China, in 11 days. Report

> Roche completes Shanghai plant expansion, starts on new project. Story

> FDA uncovers issues at Pfizer China plant after banning products from its JV partner. Article

Pharma Asia News

> China State Council briefing outlines multilevel system for medical treatment. More

> MabSpace gets $15M as Lilly Asian Ventures bets on immune approach. Story

> China's WuXi PharmaTech, Gilead focus on analytical testing in wider partnership. Article

> HK-based Chi-Med wraps up PhI healthy volunteer trial of HMPL 523. More

> China's Biomab Holding, India's Cipla go separate ways on biosimilars. Report

And Finally... GlaxoSmithKline's ($GSK) HIV-focused joint venture ViiV Healthcare said two new injectable HIV-fighters met their 32-week goals in a Phase IIb study, with details to be unveiled at a future scientific meeting. Release

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.